AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01465932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental, Proprioceptive exercises
Description: The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
Study NCT02358551 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of electrode lead through axillary vein puncture
Study NCT02358551 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of electrode lead through subclavian vein puncture
Study NCT02246686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STW5-II (Iberogast N, BAY98-7410)
Description: Application over 12 weeks 20 drops three time daily
Study NCT02246686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application over 12 weeks 20 drops three time daily
Study NCT02563418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Study NCT04464733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950
Study NCT01792609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximum Number of Screws
Description: The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
Study NCT01792609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimum Number of Screws
Description: The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
Study NCT02727413 — intervention group
Intervention type: OTHER
Intervention: Assessment of signs of organ dysfunction
Description: Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
Study NCT04104334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively
Description: NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
Study NCT04104334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices
Description: Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
Study NCT00395772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: BAY59-7939 20 mg once daily (od) for 12 weeks
Study NCT00395772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: BAY59-7939 30 mg od for 12 weeks
Study NCT00395772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: BAY59-7939 40 mg od for 12 weeks
Study NCT00395772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (LMW) Heparin + Vitamin K Antagonist
Description: Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
Study NCT04464733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03797001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg subcutaneous injection, daily for 24 weeks
Study NCT03797001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, daily for 24 weeks
Study NCT00809874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Study NCT00809874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Isolate
Study NCT00809874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Hydrolysate
Study NCT00809874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alphalact-Albumin
Study NCT02321358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-time implementation intention
Description: Will be given intervention and booster at six weeks
Study NCT02321358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-time implementation intention
Description: Will only be given the intervention once
Study NCT02321358 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
Study NCT01008397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHIST NDC#58407-012-01
Description: Oral tablet containing chlorpheniramine tannate 12mg.
Study NCT00993876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: 20 to 30 mg per day for 4 weeks
Study NCT00993876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reboxetine
Description: 4 to 8 mg per day for 4 weeks
Study NCT00993876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interpersonal psychotherapy
Study NCT01303354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Transforaminal Epidural Steroid Injection
Study NCT03320226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic 10 (Nature's Bounty)
Description: The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
Study NCT03222011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard (single) endoscopic stricture dilatation
Description: single endoscopic stricture dilatation
Study NCT03222011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive endoscopic stricture dilatation
Description: 3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
Study NCT00735254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser
Description: patient will have scar treated with pulsed dye laser
Study NCT00735254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Affirm Laser
Description: patient will have scar treated with Affirm laser
Study NCT00735254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: combined PDL and Affirm Lasers
Description: patient will have scar treated with Affirm and pulsed dye lasers
Study NCT00735254 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patient will receive no treatment
Study NCT02321358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Materials
Description: Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
Study NCT02321358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Materials
Description: Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
Study NCT03932617 — intervention group
Intervention type: DEVICE
Intervention: end tidal carbon dioxide by capnography
Description: Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states.
Study NCT04241341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
Description: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
Study NCT03959254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy post-surgical protocol for femoroacetabular impingement
Description: The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise.
Study NCT03959254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy post-surgical protocol for femoroacetabular impingement
Description: The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise.
Study NCT04790396 — intervention group
Intervention type: DEVICE
Intervention: Carotid ultrasound under pulsed-wave doppler mode
Description: Carotid ultrasound under pulsed-wave doppler mode to check whether carotid pulse is present
Study NCT04241341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction
Description: Current standard treatment at Memorial Sloan Kettering \[MSK\]).
Study NCT04241341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life questionnaires
Description: Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
Study NCT01672229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
Study NCT02161029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible drill biopsy instrument
Description: Biopsies taken with the new drill biopsy instrument for flexible endoscopy
Study NCT02161029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional biopsy instrument
Description: Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
Study NCT04241341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life questionnaires
Description: Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
Study NCT04241341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: measured by arm volume
Description: Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
Study NCT04241341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measured by arm volume
Description: Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
Study NCT04374318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: INTRATHECAL AND INTRAVENOUS
Study NCT01245413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: Adhesive to stoma bag
Study NCT01245413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Athena
Description: Adhesive to stoma bag
Study NCT02851147 — intervention group
Intervention type: DEVICE
Intervention: SL-D301
Description: Slit Lamp
Study NCT02851147 — intervention group
Intervention type: DEVICE
Intervention: DC-4
Description: Digital Camera Attachment
Study NCT02851147 — intervention group
Intervention type: DEVICE
Intervention: SL-3G
Description: Slit Lamp
Study NCT04454164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma
Study NCT04153786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporary changes in an already-implanted medical device (biventricular pacemaker)
Description: During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits.
Study NCT03953664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental-Exercise training
Description: Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
Study NCT02117505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
Study NCT02117505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5\*30 mg tablet=150 mg) in one of the treatment periods.
Study NCT00090753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
Study NCT00090753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
Study NCT00090753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Description: Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
Study NCT00090753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
Study NCT03183141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SER-109
Description: SER-109, an oral, biologically derived, live microbiome therapeutic that comprises purified bacterial spores
Study NCT01898598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo to vismodegib for 12 weeks.
Study NCT01898598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
Study NCT03092388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi Frequency Bioimpedance Analysis (mfBIA)
Description: Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.
Study NCT03092388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography/Polygraphy (PSG/PG)
Description: Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.
Study NCT03092388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Capillary Blood Gas Analysis (CBGA)
Description: CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.
Study NCT03092388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tilting Table with Hemodynamic Monitoring
Description: A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
Study NCT04454164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: serum physiologic
Study NCT02672761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR meditation
Description: Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head.